How many stocks are there of Orgenesis?
The current number of stocks of Orgenesis is 29.01 M undefined.
Orgenesis Stocks 2024
Orgenesis Stocks
29.01 M
Ticker
ORGS
ISIN
US68619K2042
WKN
A2H7XQ
In 2024, Orgenesis had 29.01 M outstanding stocks, a 0% change from the 29.01 M stocks in the previous year.
The Orgenesis Stocks history
| YEAR | NUMBER OF STOCKS (undefined USD) |
|---|---|
| 2025e | 29.01 |
| 2024e | 29.01 |
| 2023 | 29.01 |
| 2022 | 25.1 |
| 2021 | 24.27 |
| 2020 | 21.32 |
| 2019 | 15.91 |
| 2018 | 13.37 |
| 2017 | 9.68 |
| 2016 | 8.52 |
| 2015 | 4.65 |
| 2014 | 4.51 |
| 2013 | 4.21 |
| 2012 | 4.52 |
| 2011 | 6.71 |
| 2010 | 0.19 |
| 2009 | 0.19 |
| 2008 | 0.19 |
Orgenesis shares outstanding US68619K2042 · A2H7XQ
The number of shares was Orgenesis in 2023 — This indicates how many shares 29.008 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Orgenesis earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Orgenesis's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Orgenesis’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Orgenesis's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2008 | 190,000 Aktien |
| 2009 | 190,000 Aktien |
| 2010 | 190,000 Aktien |
| 2011 | 6.71 M Aktien |
| 2012 | 4.52 M Aktien |
| 2013 | 4.21 M Aktien |
| 2014 | 4.51 M Aktien |
| 2015 | 4.65 M Aktien |
| 2016 | 8.52 M Aktien |
| 2017 | 9.68 M Aktien |
| 2018 | 13.37 M Aktien |
| 2019 | 15.91 M Aktien |
| 2020 | 21.32 M Aktien |
| 2021 | 24.27 M Aktien |
| 2022 | 25.1 M Aktien |
| 2023 | 29.01 M Aktien |
| 2024e | 29.01 M Aktien |
| 2025e | 29.01 M Aktien |
Orgenesis Aktienanalyse
What does Orgenesis do?
Orgenesis Inc is a company specializing in the development of therapies for the treatment of diabetes and other diseases. The company was founded in 2008 to advance research on new therapy approaches for diabetes treatment. Its business model is based on the development of cell therapy technologies to treat patients with diabetes. The company focuses on developing therapies that use human cells to regulate the body's immune system and improve insulin production. Orgenesis Inc also offers consulting services to help other companies develop similar technologies. The company's goal is to provide technology and know-how to drive industrial progress and help people worldwide. Orgenesis Inc is divided into several areas, including biotherapeutics, where it researches and develops therapeutic cell therapies for diabetes and other chronic diseases. It also operates in the engineering services sector, assisting with the design, construction, and development of other therapies and medical devices. The company also distributes products for monitoring diabetes in patients, such as innovative devices that monitor blood glucose and other important parameters, triggering alarms when certain thresholds are exceeded. In summary, Orgenesis Inc is a leading company in the research and development of cell therapy technologies in the field of diabetes and autoimmune therapy. It engages in a wide range of activities, from consulting services to engineering tasks and marketing its own products. This "closed loop" approach of research, development, and marketing has made Orgenesis Inc an innovative company that plays a significant role in the global healthcare industry. Orgenesis ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Orgenesis's Shares Outstanding
Orgenesis's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Orgenesis’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Orgenesis’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Orgenesis’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Orgenesis stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Orgenesis are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Orgenesis evolved in recent years?
The number of shares of Orgenesis has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Orgenesis as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Orgenesis?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Orgenesis pay?
Over the past 12 months, Orgenesis paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Orgenesis is expected to pay a dividend of 0 USD.
What is the dividend yield of Orgenesis?
The current dividend yield of Orgenesis is .
When does Orgenesis pay dividends?
Orgenesis pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Orgenesis?
Orgenesis paid dividends every year for the past 0 years.
What is the dividend of Orgenesis?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Orgenesis located?
Orgenesis is assigned to the 'Health' sector.
Wann musste ich die Aktien von Orgenesis kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Orgenesis from 9/7/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/7/2024.
When did Orgenesis pay the last dividend?
The last dividend was paid out on 9/7/2024.
What was the dividend of Orgenesis in the year 2023?
In the year 2023, Orgenesis distributed 0 USD as dividends.
In which currency does Orgenesis pay out the dividend?
The dividends of Orgenesis are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Orgenesis
Our stock analysis for Orgenesis Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Orgenesis Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
